Literature DB >> 15278129

Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.

Mauro Ravera1, Sara Baracco, Claudio Cassino, Piero Zanello, Domenico Osella.   

Abstract

The imidazolium trans-tetrachloro(dimethylsulfoxide)imidazoleruthenate(III) complex [ImH][Ru(III)Cl(4)(DMSO)(Im)], NAMI-A, has shown an interesting antimetastatic activity. Since Ru(III) complexes are coordinatively more inert than the corresponding Ru(II) derivatives, an "activation by reduction" mechanism has been proposed to explain the biological activity of NAMI-A, thus acting as a pro-drug. We report here an electrochemical study on NAMI-A in aqueous solutions which emphasizes the structural and chemical consequences accompanying the easy Ru(III)/Ru(II) electron transfer (e.g., axial imidazole/water exchange in acidic solution in the short timescale of cyclic voltammetry followed by equatorial chloride/water exchange in the longer timescale of macroelectrolysis).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278129     DOI: 10.1039/b400952E

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  10 in total

1.  Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.

Authors:  Alethia A Hostetter; Michelle L Miranda; Victoria J DeRose; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2011-07-08       Impact factor: 3.358

Review 2.  Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Rita Santamaria; Carlo Irace
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

3.  Electronic structural investigations of ruthenium compounds and anticancer prodrugs.

Authors:  Travis V Harris; Robert K Szilagyi; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2009-04-07       Impact factor: 3.358

4.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Authors:  Naniye Cetinbas; Michael I Webb; Joshua A Dubland; Charles J Walsby
Journal:  J Biol Inorg Chem       Date:  2009-08-26       Impact factor: 3.358

5.  The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.

Authors:  Malgorzata Brindell; Iwona Stawoska; Justyna Supel; Andrzej Skoczowski; Grazyna Stochel; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2008-04-26       Impact factor: 3.358

6.  Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.

Authors:  Angela Casini; Guido Mastrobuoni; Mattia Terenghi; Chiara Gabbiani; Enrico Monzani; Gloriano Moneti; Luigi Casella; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2007-08-07       Impact factor: 3.358

7.  Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution.

Authors:  Malgorzata Brindell; Dorota Piotrowska; Azza A Shoukry; Grazyna Stochel; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2007-05-15       Impact factor: 3.358

8.  Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.

Authors:  Carlo Irace; Gabriella Misso; Antonella Capuozzo; Marialuisa Piccolo; Claudia Riccardi; Alessandra Luchini; Michele Caraglia; Luigi Paduano; Daniela Montesarchio; Rita Santamaria
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

Review 9.  Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity.

Authors:  Claudia Riccardi; Domenica Musumeci; Marco Trifuoggi; Carlo Irace; Luigi Paduano; Daniela Montesarchio
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-26

10.  Ru(III) Complexes with Lonidamine-Modified Ligands.

Authors:  Ilya A Shutkov; Yulia N Okulova; Vladimir Yu Tyurin; Elena V Sokolova; Denis A Babkov; Alexander A Spasov; Yulia A Gracheva; Claudia Schmidt; Kirill I Kirsanov; Alexander A Shtil; Olga M Redkozubova; Elena F Shevtsova; Elena R Milaeva; Ingo Ott; Alexey A Nazarov
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.